Kiwoom Securities published a new report on D&D Pharmatech (347850) titled "The Golden Ratio of GLP/GCG Toward Best in Class," drawing attention to the company's clinical competitiveness. However, the report did not provide an investment opinion or a target price.

Kiwoom Securities explained that additional data was disclosed during an investor relations (IR) session held after the top-line results were announced at the recent European Association for the Study of the Liver (EASL) conference. CEO Lee Seul-gi reportedly attended the session to detail the clinical results and future development strategies.

According to the report, consistent fibrosis improvement effects were confirmed across three independent analytical methods. Based on this, Kiwoom Securities positively assessed that the objectivity and reliability of the clinical results have been further enhanced.

Furthermore, the firm projected that market expectations regarding the future technology transfer deal structure and the selection process for a global pharmaceutical partner will expand. In particular, it analyzed that if the objectivity and reproducibility of the clinical data are confirmed, it will work favorably in strengthening the company's negotiating position with global pharmaceutical companies.

Amid such positive assessments, D&D Pharmatech's stock price showed strength on the morning of the 17th, trading at 93,000 won, up 1,400 won from the previous trading day. Investors are closely monitoring the future disclosure of additional clinical results and the progress of technology transfer negotiations.

[※ This article was written with the assistance of AI. Investment decisions are the responsibility of the investor, and the content included in this article may be subject to change depending on market conditions.]